Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed from the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg

Journal of Pharmaceutical Sciences

Volumn 105, Issue 2, 2016, Pages 431-442

  Tanaka, Yuta ^a   Kitamura, Yoshiaki ^a   Maeda, Kazuya ^b   Sugiyama, Yuichi ^c  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

Author keywords

ABC transporters; intestinal absorption; intestinal metabolism; mathematical model; passive diffusion transport

Indexed keywords

CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; DRUG;

ANATOMIC MODEL; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; FECES ANALYSIS; GRAPEFRUIT JUICE; HUMAN; INTESTINAL AVAILABILITY; INTESTINE ABSORPTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; ANIMAL; CHEMISTRY; DRUG EFFECTS; INTESTINE; METABOLISM; PHYSIOLOGY; THEORETICAL MODEL;

ADMINISTRATION, ORAL; ANIMALS; CYTOCHROME P-450 CYP3A; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MODELS, THEORETICAL; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS;

EID: 84964458803     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2015.11.005     Document Type: Review

References (61)

1. G.R. Wilkinson Clearance approaches in pharmacology Pharmacol Rev 39 1 1987 1 47
2. J.H. Lin, M. Chiba, and T.A. Baillie Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51 2 1999 135 158
3. I. Tamai Oral drug delivery utilizing intestinal OATP transporters Adv Drug Deliv Rev 64 6 2012 508 514
4. H. Glaeser, D.G. Bailey, G.K. Dresser, and et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans Clin Pharmacol Ther 81 3 2007 362 370
5. Y. Zhang, J. Sun, Y. Sun, Y. Wang, and Z. He Prodrug design targeting intestinal PepT1 for improved oral absorption: design and performance Curr Drug Metab 14 6 2013 675 687
6. K.E. Pedersen, B.D. Christiansen, N.A. Klitgaard, and F. Nielsen-Kudsk Effect of quinidine on digoxin bioavailability Eur J Clin Pharmacol 24 1 1983 41 47
7. H. Kusuhara, H. Furuie, A. Inano, and et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP Br J Pharmacol 166 6 2012 1793 1803
8. Y. Tanaka, Y. Kitamura, K. Maeda, and Y. Sugiyama Quantitative analysis of the ABCG2 c.421C>A polymorphism effect on in vivo transport activity of breast cancer resistance protein (BCRP) using an intestinal absorption model J Pharm Sci 104 9 2015 3039 3048
9. Y. Kitamura, H. Kusuhara, and Y. Sugiyama Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine J Pharmacol Exp Ther 332 2 2010 659 666
10. A. Rao, J. Haywood, A.L. Craddock, M.G. Belinsky, G.D. Kruh, and P.A. Dawson The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis Proc Natl Acad Sci U S A 105 10 2008 3891 3896
11. J.W. Jonker, E. Wagenaar, C.A. Mol, and et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene Mol Cell Biol 21 16 2001 5471 5477
12. D.S. Wang, J.W. Jonker, Y. Kato, H. Kusuhara, A.H. Schinkel, and Y. Sugiyama Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin J Pharmacol Exp Ther 302 2 2002 510 515
13. L.S. Kaminsky, and Q.Y. Zhang The small intestine as a xenobiotic-metabolizing organ Drug Metab Dispos 31 12 2003 1520 1525
14. T. Imai, and K. Ohura The role of intestinal carboxylesterase in the oral absorption of prodrugs Curr Drug Metab 11 9 2010 793 805
15. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 "pie" Drug Metab Dispos 34 5 2006 880 886
16. M. Kato, K. Chiba, A. Hisaka, and et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature Drug Metab Pharmacokinet 18 6 2003 365 372
17. M. Gertz, J.D. Davis, A. Harrison, J.B. Houston, and A. Galetin Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations Curr Drug Metab 9 8 2008 785 795
18. M. Gertz, A. Harrison, J.B. Houston, and A. Galetin Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data Drug Metab Dispos 38 7 2010 1147 1158
19. R.B. Kim, C. Wandel, B. Leake, and et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein Pharm Res 16 3 1999 408 414
20. K.T. Kivisto, M. Niemi, and M.F. Fromm Functional interaction of intestinal CYP3A4 and P-glycoprotein Fundam Clin Pharmacol 18 6 2004 621 626
21. Y. Zhang, X. Guo, E.T. Lin, and L.Z. Benet Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor Drug Metab Dispos 26 4 1998 360 366
22. K.S. Lown, R.R. Mayo, A.B. Leichtman, and et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine Clin Pharmacol Ther 62 3 1997 248 260
23. L.Z. Benet, T. Izumi, Y. Zhang, J.A. Silverman, and V.J. Wacher Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery J Control Release 62 1-2 1999 25 31
24. V.J. Wacher, J.A. Silverman, Y. Zhang, and L.Z. Benet Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J Pharm Sci 87 11 1998 1322 1330
25. R.A. van Waterschoot, and A.H. Schinkel A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice Pharmacol Rev 63 2 2011 390 410
26. M. Estudante, J.G. Morais, G. Soveral, and L.Z. Benet Intestinal drug transporters: an overview Adv Drug Deliv Rev 65 10 2013 1340 1356
27. B.M. Johnson, W. Chen, R.T. Borchardt, W.N. Charman, and C.J. Porter A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum J Pharmacol Exp Ther 305 1 2003 151 158
28. A. Galetin, M. Gertz, and J.B. Houston Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions Expert Opin Drug Metab Toxicol 4 7 2008 909 922
29. A. Hisaka, M. Nakamura, A. Tsukihashi, S. Koh, and H. Suzuki Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions Drug Metab Dispos 42 10 2014 1640 1645
30. Y. Mano, Y. Sugiyama, and K. Ito Use of a physiologically based pharmacokinetic model for quantitative prediction of drug-drug interactions via CYP3A4 and estimation of the intestinal availability of CYP3A4 substrates J Pharm Sci 104 9 2015 3183 3193
31. Y.H. Zhao, J. Le, M.H. Abraham, and et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors J Pharm Sci 90 6 2001 749 784
32. M.V. Varma, R.S. Obach, C. Rotter, and et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination J Med Chem 53 3 2010 1098 1108
33. Y.H. Zhao, M.H. Abraham, J. Le, and et al. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption Eur J Med Chem 38 3 2003 233 243
34. P. Artursson, and J. Karlsson Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem Biophys Res Commun 175 3 1991 880 885
35. W.L. Chiou, and A. Barve Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats Pharm Res 15 11 1998 1792 1795
36. W.L. Chiou, and P.W. Buehler Comparison of oral absorption and bioavailablity of drugs between monkey and human Pharm Res 19 6 2002 868 874
37. K. Kadono, T. Akabane, K. Tabata, K. Gato, S. Terashita, and T. Teramura Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor Drug Metab Dispos 38 7 2010 1230 1237
38. D. Cong, M. Doherty, and K.S. Pang A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism Drug Metab Dispos 28 2 2000 224 235
39. K.S. Pang, and E.C. Chow Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model Drug Metab Dispos 40 10 2012 1869 1877
40. E.C. Chow, and K.S. Pang Why we need proper PBPK models to examine intestine and liver oral drug absorption Curr Drug Metab 14 1 2013 57 79
41. K. Ito, H. Kusuhara, and Y. Sugiyama Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach Pharm Res 16 2 1999 225 231
42. J. Yang, M. Jamei, K.R. Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of intestinal first-pass drug metabolism Curr Drug Metab 8 7 2007 676 684
43. A. Hisaka, Y. Ohno, T. Yamamoto, and H. Suzuki Theoretical considerations on quantitative prediction of drug-drug interactions Drug Metab Pharmacokinet 25 1 2010 48 61
44. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv Drug Deliv Rev 50 Suppl 1 2001 S41 67
45. M. Jamei, G.L. Dickinson, and A. Rostami-Hodjegan A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates Drug Metab Pharmacokinet 24 1 2009 53 75
46. A.S. Darwich, S. Neuhoff, M. Jamei, and A. Rostami-Hodjegan Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model Curr Drug Metab 11 9 2010 716 729
47. J.M. DeSesso, and C.F. Jacobson Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats Food Chem Toxicol 39 3 2001 209 228
48. M.B. Bolger, V. Lukacova, and W.S. Woltosz Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine AAPS J 11 2 2009 353 363
49. Y. Sugiyama, and T. Ooie Prediction of pharmacokinetics based on in vitro data Methods and Techniques for Pharmacokinetic Studies 1993 Japanese Society for the Study of Xenobiotics Tokyo 87 108
50. M.J. Hanley, P. Cancalon, W.W. Widmer, and D.J. Greenblatt The effect of grapefruit juice on drug disposition Expert Opin Drug Metab Toxicol 7 3 2011 267 286
51. S. Wason, J.L. DiGiacinto, and M.W. Davis Effects of grapefruit and Seville orange juices on the pharmacokinetic properties of colchicine in healthy subjects Clin Ther 34 10 2012 2161 2173
52. A. Moller, K. Iwasaki, A. Kawamura, and et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects Drug Metab Dispos 27 6 1999 633 636
53. G.J. Muirhead, D.J. Rance, D.K. Walker, and P. Wastall Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil Br J Clin Pharmacol 53 Suppl 1 2002 13S 20S
54. C. Liu, Y.F. Shang, X.F. Zhang, and et al. Co-administration of grapefruit juice increases bioavailability of tacrolimus in liver transplant patients: a prospective study Eur J Clin Pharmacol 65 9 2009 881 885
55. T. Tachibana, M. Kato, and Y. Sugiyama Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values Pharm Res 29 3 2012 651 668
56. A. Jetter, M. Kinzig-Schippers, M. Walchner-Bonjean, and et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil Clin Pharmacol Ther 71 1 2002 21 29
57. J. Lundahl, C.G. Regardh, B. Edgar, and G. Johnsson Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects Eur J Clin Pharmacol 49 1-2 1995 61 67
58. D.G. Bailey, J. Malcolm, O. Arnold, and J.D. Spence Grapefruit juice-drug interactions Br J Clin Pharmacol 46 2 1998 101 110
59. K. Maeda, and Y. Sugiyama Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs Drug Metab Pharmacokinet 23 4 2008 223 235
60. T. Watanabe, K. Maeda, C. Nakai, and Y. Sugiyama Investigation of the effect of the uneven distribution of CYP3A4 and P-glycoprotein in the intestine on the barrier function against xenobiotics: a simulation study J Pharm Sci 102 9 2013 3196 3204
61. T. Saeki, K. Ueda, Y. Tanigawara, R. Hori, and T. Komano Human P-glycoprotein transports cyclosporin A and FK506 J Biol Chem 268 9 1993 6077 6080